| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015 | 4074 | 2015 |
| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3700 | 2019 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 2008 | 2014 |
| Chimeric antigen receptor T cells in refractory B-cell lymphomas SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Ö Anak, ... New England Journal of Medicine 377 (26), 2545-2554, 2017 | 1867 | 2017 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1258 | 2014 |
| Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Journal of clinical oncology 34 (23), 2698-2704, 2016 | 1086 | 2016 |
| Utility of FDG-PET scanning in lymphoma by WHO classification R Elstrom, L Guan, G Baker, K Nakhoda, JA Vergilio, H Zhuang, S Pitsilos, ... Blood, The Journal of the American Society of Hematology 101 (10), 3875-3876, 2003 | 587 | 2003 |
| PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR EA Chong, JJ Melenhorst, SF Lacey, DE Ambrose, V Gonzalez, BL Levine, ... Blood, The Journal of the American Society of Hematology 129 (8), 1039-1041, 2017 | 506 | 2017 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 455 | 2018 |
| Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients1 DE Tsai, CL Hardy, JE Tomaszewski, RM Kotloff, KM Oltoff, BG Somer, ... Transplantation 71 (8), 1076-1088, 2001 | 453 | 2001 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 444 | 2022 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 424 | 2021 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 423 | 2021 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 420 | 2022 |
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ... Annals of Oncology 28 (7), 1436-1447, 2017 | 369 | 2017 |
| Treatment of PTLD with rituximab or chemotherapy RL Elstrom, C Andreadis, NA Aqui, VN Ahya, RD Bloom, SC Brozena, ... American Journal of Transplantation 6 (3), 569-576, 2006 | 298 | 2006 |
| Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ... The Lancet Oncology 23 (8), 1055-1065, 2022 | 296 | 2022 |
| Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma J Ruan, P Martin, B Shah, SJ Schuster, SM Smith, RR Furman, P Christos, ... New England Journal of Medicine 373 (19), 1835-1844, 2015 | 286 | 2015 |
| Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma SJ Schuster, SS Neelapu, BL Gause, JE Janik, FM Muggia, ... Journal of clinical oncology 29 (20), 2787-2794, 2011 | 282 | 2011 |
| Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results JP Leonard, M Coleman, JC Ketas, A Chadburn, R Furman, MW Schuster, ... Clinical Cancer Research 10 (16), 5327-5334, 2004 | 272 | 2004 |
